Drug intelligence / Profile preview

HTPEP-003

Development stage: Preclinical
Lead developer: Chengdu Huitai Biomedical
Modality: Peptides

Overview

HTPEP-003 is a peptide-based therapeutic candidate developed by Chengdu Huitai Biopharmaceutical for the treatment of renal fibrosis. It functions as an inhibitor of Transforming Growth Factor beta 1 (TGF-β1) signaling, a central mediator in the pathogenesis of fibrotic diseases. By targeting TGF-β1, HTPEP-003 aims to mitigate the excessive accumulation of extracellular matrix proteins in the kidneys, thereby slowing or reversing the progression of renal fibrosis. The drug is currently in preclinical development as part of a broader pipeline of TGF-β1-targeted peptides.

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)

Beyond the preview

Go deeper on HTPEP-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTPEP-003.

Explore the full profile